Payment overview · 2025
General Payments
$2,802.54
44 reported records · 14 companies
Healthcare provider profile · identity verified
Tucker James Harrison, DO
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · TULSA, OK · NPI 1396004636
Verified facts
What the public records show
CMS Open Payments records show Tucker James Harrison, DO received $2,802.54 in general payments during 2025 across 44 reported records.
Stryker Corporation accounted for 41.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $1,164.25 | 41.5% | 12 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $458.46 | 16.4% | 3 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $229.70 | 8.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $192.32 | 6.9% | 6 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $191.04 | 6.8% | 7 | 2025 |
| Surmodics, Inc. | Unresolved — no canonical attribution shown | $157.26 | 5.6% | 2 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $151.24 | 5.4% | 3 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $106.65 | 3.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $55.41 | 2.0% | 2 | 2025 |
| Mozarc Medical US LLC | Unresolved — no canonical attribution shown | $24.63 | 0.9% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $22.53 | 0.8% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.30 | 0.7% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $16.30 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.45 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,531.98 | 43 |
| Travel and Lodging | $270.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc., Stryker Corporation | $663.78 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc., Stryker Corporation | $663.78 | 5 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $542.40 | 7 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $458.46 | 3 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $229.70 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy Normalized: pounce thrombectomy |
Device | Surmodics, Inc. | $157.26 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Thrombectomy System Normalized: pounce thrombectomy system |
Device | Surmodics, Inc. | $157.26 | 2 | 2025 |
Source payment records
|
|||||
| Pounce Venous Thrombectomy System Normalized: pounce venous thrombectomy system |
Device | Surmodics, Inc. | $157.26 | 2 | 2025 |
Source payment records
|
|||||
| Sublime 014 Rx PTA Balloon Dilatation Catheter Normalized: sublime 014 rx pta balloon dilatation catheter |
Device | Surmodics, Inc. | $157.26 | 2 | 2025 |
Source payment records
|
|||||
| Sublime Microcatheter, 018, 200cm, Straight Normalized: sublime microcatheter 018 200cm straight |
Device | Surmodics, Inc. | $157.26 | 2 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $151.24 | 3 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $102.95 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $45.20 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| General - Stents Normalized: general stents |
Device | Boston Scientific Corporation | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| PALINDROME Normalized: palindrome |
Device | Mozarc Medical US LLC | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $22.53 | 1 | 2025 |
Source payment records
|
|||||
| VENACORE THROMBECTOMY CATHETER Normalized: venacore thrombectomy catheter |
Device | Stryker Corporation | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| MCOT Normalized: mcot |
Device | Philips North America LLC | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| Rotablator Rotational Atherectomy System Console Kit Normalized: rotablator rotational atherectomy system console kit |
Device | Boston Scientific Corporation | $12.22 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $4.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 369 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 277 | 74 |
| Eliquis | Apixaban | 259 | 59 |
| Losartan Potassium | Losartan Potassium | 230 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 68 |
| Furosemide | Furosemide | 149 | 56 |
| Xarelto | Rivaroxaban | 142 | 33 |
| Carvedilol | Carvedilol | 116 | 36 |
| Lisinopril | Lisinopril | 115 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 113 | 31 |
| Spironolactone | Spironolactone | 102 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 21 |
| Chlorthalidone | Chlorthalidone | 70 | 21 |
| Potassium Chloride | Potassium Chloride | 60 | 20 |
| Ezetimibe | Ezetimibe | 59 | 16 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Cilostazol | Cilostazol | 58 | 15 |
| Methylprednisolone | Methylprednisolone | 52 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | 14 |
| Entresto | Sacubitril/Valsartan | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | 11 |
| Torsemide | Torsemide | 23 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Repatha Syringe | Evolocumab | 17 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,802.54 · 44 records | Stryker Corporation | ALPHAVAC, AVVIGO Guidance System, Assure WCD, Attruby, CLOTTRIEVER BOLD CATHETER, CT THROMBECTOMY SYSTEM KIT, ENTRESTO, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Balloon Catheters, General - Stents, Indigo System, LEQVIO, MCOT, PALINDROME, Pounce Thrombectomy, Pounce Thrombectomy System, Pounce Venous Thrombectomy System, REPATHA, Ranger, Rotablator Rotational Atherectomy System Console Kit, SYMPHONY CATHETER, Sublime 014 Rx PTA Balloon Dilatation Catheter, Sublime Microcatheter, 018, 200cm, Straight, VENACORE THROMBECTOMY CATHETER, WATCHMAN FLX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novartis Pharmaceuticals Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error